Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin Bioequivalence Study in Jordan
NCT05229796Phase 1Completed
- Start
- May 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM). Primary endpoint: Plasma concentration of empagliflozin at 5 months. Started May 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05229796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05229796.